Titan Pharmaceuticals, Inc. (TTNP)
| Market Cap | 22.19M |
| Revenue (ttm) | 4.84M |
| Net Income (ttm) | -18.24M |
| Shares Out | 3.77M |
| EPS (ttm) | -4.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $2.34 |
| Previous Close | $2.35 |
| Change ($) | -0.01 |
| Change (%) | -0.43% |
| Day's Open | 2.35 |
| Day's Range | 2.22 - 2.37 |
| Day's Volume | 122,652 |
| 52-Week Range | 2.15 - 14.06 |
SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decembe...
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potenc...
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institut...
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 rever...
The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30...
Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0....
Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Investors to Kn...
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing...
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved th...
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its certificate...
SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. ...
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 202...
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript
On Wednesday, August 14, Titan Pharmaceuticals (NASDAQ: TTNP) will release its latest earnings report.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2018 Results - Earnings Call Transcript
About TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment ... [Read more...]
| Industry Biotechnology | IPO Date Jan 18, 1996 |
| Stock Exchange NASDAQ | Ticker Symbol TTNP |
Financial Performance
In 2020, TTNP's revenue was $4.84 million, an increase of 85.72% compared to the previous year's $2.61 million. Losses were -$18.24 million, 10.8% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for TTNP stock is "Buy" and the 12-month stock price forecast is 7.00.